Abstract 2665
Background
To investigate the influence of enteral nutrition on body weight, nutritional status, treatment toxicities, and short-term outcomes in esophageal carcinoma patients with concurrent chemoradiotherapy (CCRT).
Methods
Eigible patients were randomly assigned (2:1 ratio) to EN group or control group. The primary endpoint was the change in body weight from baseline after treatment. The secondary endpoints were nutrition related blood parameter changes, treatment toxicities and outcomes.
Results
Between Mar. 2015 and Jun. 2017, 222 patients from ten hospitals were randomised into the EN group (n = 148) and the control group (n = 74). Patients in EN group lost less body weight compared with the control group (P<.0.05). Participants who received EN had less decline than controls in serum albumin and hemoglobin (P < 0.05). There was no difference in total lymphocyte counts in the two groups. Grade 3/4 leukopenia and infection rates were significantly more frequent in the control group than in the EN group (P < 0.05). Radiation pneumonitis and esophagitis tended to be less frequent in the EN group, albeit insignificantly. Patients supported on EN experienced greater chemoradiotherapy completion rates. There was no significant difference in tumor response between two groups (P > 0.05).
Conclusions
Enteral nutrition can reduce the weight loss of esophageal cancer patients during chemoradiotherapy, improve nutritional status, treatment tolerance, reduce toxicity.
Clinical trial identification
NCT 02399306.
Legal entity responsible for the study
Tao Li.
Funding
Has not received any funding.
Editorial Acknowledgement
none
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5302 - Preliminary Results of a Ph2a Study to Evaluate the Clinical Efficacy and Safety of Erdafitinib in Asian Patients with Biomarker-Selected Advanced Cholangiocarcinoma (CCA)
Presenter: Yen-Yang Chen
Session: Poster Discussion session -Gastrointestinal, non-colorectal
Resources:
Abstract
Poster Discussion session -Gastrointestinal, non-colorectal - Invited Discussant LBA28, 623PD and 624PD
Presenter: Ian Chau
Session: Poster Discussion session -Gastrointestinal, non-colorectal
Resources:
Slides
Webcast
2247 - CARRIE: A Randomized, Double-blind, Placebo-controlled Phase 2 Study of Istiratumab (MM-141) plus Nab-Paclitaxel and Gemcitabine versus Nab-Paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer
Presenter: Andrew Ko
Session: Poster Discussion session -Gastrointestinal, non-colorectal
Resources:
Abstract
4525 - Pembrolizumab for advanced biliary adenocarcinoma: Results from the multicohort, phase 2 KEYNOTE-158 study
Presenter: Makoto Ueno
Session: Poster Discussion session -Gastrointestinal, non-colorectal
Resources:
Abstract
2025 - Randomized, Phase III Trial Comparing Adjuvant Gemcitabine (Gem) versus Gem plus Chemoradiation (CCRT) in Curatively Resected Pancreatic Ductal Adenocarcinoma (PDAC) – A Taiwan Cooperative Oncology Group Study
Presenter: Hui-Ju Chang
Session: Poster Discussion session -Gastrointestinal, non-colorectal
Resources:
Abstract
Poster Discussion session -Gastrointestinal, non-colorectal - Invited Discussant LBA29, 625PD and 626PD
Presenter: Eileen O'Reilly
Session: Poster Discussion session -Gastrointestinal, non-colorectal
Resources:
Slides
Webcast
Poster Discussion session -Gastrointestinal, non-colorectal - Invited Discussant 618PD abd 620PD
Presenter: Marcel Verheij
Session: Poster Discussion session -Gastrointestinal, non-colorectal